½ÃÀ庸°í¼­
»óǰÄÚµå
1587802

ADME µ¶¼º ½ÃÇè ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ±â¼úº°, ¿ëµµº°, ¹æ¹ýº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)

ADME Toxicology Testing Market Size, Share & Trends Analysis Report By Technology (Cell Culture Tech, High Throughput Tech, Molecular Imaging), By Application, By Method, By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ADME µ¶¼º ½ÃÇè ½ÃÀå ¼ºÀå ¹× µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ADME µ¶¼º ½ÃÇè ¼¼°è ½ÃÀå ±Ô¸ð´Â 2025³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 10.0%ÀÇ CAGR·Î È®´ëµÇ¾î 2030³â¿¡´Â 114¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¦¾àȸ»çµéÀÌ º¸´Ù ÀûÀýÇÑ µ¶¼º ½ÃÇè ¹æ¹ýÀ» äÅÃÇÏ¿© Èı⠴ܰèÀÇ ¾à¹° ½ÇÆÐ¸¦ È®ÀÎÇØ¾ß ÇÒ Çʿ伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ ½ÃÀåÀÇ ¼öÀÍ Ã¢ÃâÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Èí¼ö-ºÐÆ÷-´ë»ç-¹è¼³(ADME) µ¶¼º ½ÃÇèÀº ÀÓ»ó½ÃÇè¿¡¼­ ºÐÀÚ°¡ À¯¹ßÇÏ´Â µ¶¼º ¹ÝÀÀÀ» È­ÇÐÀû, ¾à¸®ÇÐÀû, À¯ÀüÀû ¿äÀÎ ¹× Àü½Å ¹ÝÀÀ¿¡ ´ëÇØ ½ÃÇèÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ÀÌ·¯ÇÑ µ¶¼º ½ÃÇè ÀýÂ÷´Â Åõ¿© ½Ã ü³» µ¶¼º ¹ÝÀÀÀ» Á¦ÇÑÇϰųª ¿¹¹æÇÏ´Â È¿°úÀûÀÎ ÀǾàǰ °³¹ß¿¡ µµ¿òÀÌ µË´Ï´Ù. µ¶¼º ¼öÁØÀº ¾à¹°°ú ¼÷ÁÖ »çÀÌÀÇ °ÅÀÇ ½Ç½Ã°£ ¹ÝÀÀÀ» ³ªÅ¸³»´Â ÀÚ¿¬¿¡ °¡±î¿î Á¶°Ç¿¡¼­ ¼öÇàµÇ´Â ÀÏ·ÃÀÇ Å×½ºÆ® °á°ú¸¦ ±â¹ÝÀ¸·Î °áÁ¤µË´Ï´Ù.

2017³â ÇöÀç ADME µ¶¼º ½ÃÇè ºÐ¾ßÀÇ ¾à 43.0%°¡ ¼¼Æ÷¹è¾ç ±â¼úÀ» ±â¹ÝÀ¸·Î ¼öÇàµÇ°í ÀÖ½À´Ï´Ù. ¼¼Æ÷¹è¾ç ±â¼úÀº ÀÚ¿¬¿¡ °¡±î¿î Á¶°Ç°ú ¼¼Æ÷ ¼öÁØ¿¡¼­ ¾òÀ» ¼ö ÀÖ´Â Á¤È®ÇÑ °á°ú µîÀÇ ÀåÁ¡À¸·Î ÀÎÇØ ³Î¸® äÅõǰí ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ ºÐ¼®Àº ¿©·¯ À¯ÇüÀÇ µ¶¼º ¹ÝÀÀ ¶Ç´Â µ¶¼º ¹ÝÀÀÀÌ ¹ß»ýÇÒ ¼ö ÀÖ´Â ½Ã½ºÅÛ¿¡ ´ëÇØ ¼öÇàµË´Ï´Ù. µ¶¼º ½ÃÇè¿¡´Â Àü½Å µ¶¼º, ½ÅÀå µ¶¼º, °£ µ¶¼º, ½Å°æ µ¶¼º ¹× ±âŸ »ýü Á¶Á÷¿¡¼­ ¹ß»ýÇÒ ¼ö ÀÖ´Â µ¶¼º µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÇè ¹æ¹ýÀÇ Ãß¼¼´Â ÇöÀç ÁøÇà ÁßÀ̰í, ¸¹Àº Á¦¾àȸ»çµéÀÌ ÀÌ·¯ÇÑ ½ÃÇè ¹æ¹ýÀ» µµÀÔÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ´Â ½Å¾à °³¹ß °úÁ¤À» °¡¼ÓÈ­ÇÏ°í ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ADME µ¶¼º ½ÃÇè ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • Èı⠴ܰèÀÇ ÀǾàǰ ½ÇÆÐ ºñÀ²ÀÌ Áõ°¡ÇÏ¿© ÀǾàǰ °³¹ßÀ» À§ÇÑ ±ÍÁßÇÑ ½Ã°£°ú ÅõÀÚ ¼Õ½ÇÀÌ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, OMICS ±â¼úÀÇ ¼ºÀå°ú äÅà Áõ°¡´Â ÇâÈÄ ¸î ³â µ¿¾È ¼öÀÍ Ã¢ÃâÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ºÏ¹Ì´Â ¸¹Àº Á¦¾àȸ»çµéÀÌ »õ·Î¿î ºÐÀÚÀÇ »ó¾÷Àû Ãâ½Ã¸¦ À§ÇØ °æÀïÇϰí ÀÖ¾î ADME µ¶¼º ½ÃÇèÀÇ °¡Àå Å« ½ÃÀåÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.
  • ¾Æ½Ã¾ÆÅÂÆò¾ç°ú ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ½ÅÈï±¹ ½ÃÀåÀº ¸¹Àº ´Ù±¹Àû ±â¾÷°ú ÇöÁö ±â¾÷µéÀÌ ½ÃÀå ÁøÀÔÀ» ¸ñÇ¥·Î Çϰí Àֱ⠶§¹®¿¡ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, Çõ½Å°ú ¼ºÀå ±âȸ°¡ ÀÖ´Â ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­Çϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óºÎ ½ÃÀå Àü¸Á
    • °ü·Ã/º¸Á¶ ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ¾÷°è ºÐ¼® Åø
    • Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
    • COVID-19ÀÇ ¿µÇ⠺м®

Á¦4Àå ADME µ¶¼º ½ÃÇè ½ÃÀå : ±â¼ú ºñÁî´Ï½º ºÐ¼®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ADME µ¶¼º ½ÃÇè ½ÃÀå º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ ADME µ¶¼º ½ÃÇè ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ±â¼úº°, 2018-2030³â
  • ¼¼Æ÷¹è¾ç ±â¼ú
  • ÇÏÀÌ ½º·çDz ±â¼ú
  • ºÐÀÚ À̹Ì¡
  • ¿À¹Í½º ±â¼ú

Á¦5Àå ADME µ¶¼º ½ÃÇè ½ÃÀå : ¹æ¹ý ºñÁî´Ï½º ºÐ¼®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ADME µ¶¼º ½ÃÇè ½ÃÀå º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ ADME µ¶¼º ½ÃÇè ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¹æ¹ýº°, 2018-2030³â
  • ¼¼Æ÷ ¾î¼¼ÀÌ
  • »ýÈ­ÇÐ ºÐ¼®
  • ½Ã¹Ä·¹À̼Ç
  • »ýü¿Ü

Á¦6Àå ADME µ¶¼º ½ÃÇè ½ÃÀå : ¿ëµµ ºñÁî´Ï½º ºÐ¼®

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ADME µ¶¼º ½ÃÇè ½ÃÀå º¯µ¿ ºÐ¼®
  • ¼¼°èÀÇ ADME µ¶¼º ½ÃÇè ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¿ëµµº°, 2018-2030³â
  • Àü½Å µ¶¼º
  • ½Åµ¶¼º
  • °£µ¶¼º
  • ½Å°æ µ¶¼º
  • ±âŸ

Á¦7Àå ADME µ¶¼º ½ÃÇè ½ÃÀå : ±â¼ú, ¹æ¹ý, ¿ëµµº° Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ª ½ÃÀå ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®, 2018-2030³â
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ű¹
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦8Àå °æÀï »óȲ

  • ÁøÃâ ±â¾÷
  • ±â¾÷ ½ÃÀå »óȲ ºÐ¼®, 2024³â
  • ÁøÃâ ±â¾÷ °³¿ä
    • Thermo Fisher Scientific Inc.
    • Danaher
    • Charles River Laboratories
    • Promega Corporation
    • Agilent Technologies, Inc.
    • Curia Global, Inc.
    • Dassault Systemes
    • Catalent, Inc
    • Labcorp
    • Eurofins Scientific
    • Miltenyi Biotec
    • IQVIA Inc.
ksm 24.11.25

ADME Toxicology Testing Market Growth & Trends:

The global ADME toxicology testing market size is expected to reach USD 11.44 billion by 2030, expanding at a CAGR of 10.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Factors such as increased need to check late-stage drug failures with the adoption of more appropriate toxicity testing methods by pharmaceutical companies are expected to aid revenue generation for the market.

Absorption, distribution, metabolism, and excretion (ADME) toxicology testing is used to test toxic reactions caused by molecules in clinical trials on factors and systemic reactions such as chemical, pharmaceutical, and genetic. These toxicology testing procedures help in effective drug development, which limits or prevents toxic reactions to the body when administered. Toxicity levels are decided on the results of a series of tests conducted in near-natural conditions, which represent almost real-time reactions between the drug and the host.

As of 2017, approximately 43.0% of ADME toxicology testing areas carried out are based on cell culture tech. Cell culture technology is adopted widely owing to advantages such as near-natural conditions and accurate results obtained at a cellular level.

These assays are conducted for several types of toxic reactions or systems where toxic reactions might take place. Some of the toxicity tests are systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and other toxicities that might result in living tissue. Advancements in testing methods are underway and this trend is likely to be picked up by many companies developing drug molecules. This will speed up the drug discovery process and boost the market growth.

ADME Toxicology Testing Market Report Highlights:

  • The market is driven by an increasing ratio of late-stage drug failures, resulting in loss of valuable time and investment for drug development. Growth and increasing adoption of OMICS technology is also expected to boost revenue generation in the coming years
  • North America is the largest market for ADME toxicology testing owing to the presence of a large number of pharmaceutical companies competing for the commercial launch of novel molecules
  • Developing regions of Asia Pacific and Latin America are set to grow considerably as many multinational and local players are striving to enter the market. They are also looking to improve their hold in markets that present innovation and growth opportunities

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology
    • 1.2.2. Method
    • 1.2.3. Application
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. High rate of late-stage drug failure
      • 3.2.1.2. Increasing need for novel drug molecules
      • 3.2.1.3. Technological advancements in ADME studies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Challenges pertaining to in vitro ADME studies
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. ADME Toxicology Testing Market: Technology Business Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global ADME Toxicology Testing Market Movement Analysis
  • 4.3. Global ADME Toxicology Testing Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
  • 4.4. Cell Culture Tech
    • 4.4.1. Global Cell Culture Tech Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. High Throughput Tech
    • 4.5.1. Global High Throughput Tech Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Molecular Imaging
    • 4.6.1. Global Molecular Imaging Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. OMICS Tech
    • 4.7.1. Global OMICS Tech Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. ADME Toxicology Testing Market: Method Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global ADME Toxicology Testing Market Movement Analysis
  • 5.3. Global ADME Toxicology Testing Market Size & Trend Analysis, by Method, 2018 to 2030 (USD Million)
  • 5.4. Cellular Assay
    • 5.4.1. Global Cellular Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Biochemical Assay
    • 5.5.1. Global Biochemical Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. In Silico
    • 5.6.1. Global In Silico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Ex-vivo
    • 5.7.1. Global Ex-vivo Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. ADME Toxicology Testing Market: Application Business Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global ADME Toxicology Testing Market Movement Analysis
  • 6.3. Global ADME Toxicology Testing Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 6.4. Systemic Toxicity
    • 6.4.1. Global Systemic Toxicity Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Renal Toxicity
    • 6.5.1. Global Renal Toxicity Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Hepatotoxicity
    • 6.6.1. Global Hepatotoxicity Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Neurotoxicity
    • 6.7.1. Global Neurotoxicity Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Others
    • 6.8.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. ADME Toxicology Testing Market: Regional Estimates & Trend Analysis by Technology, Method, & Application

  • 7.1. Regional Market Dashboard
  • 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
  • 7.3. North America
    • 7.3.1. North America ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. U.S. ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Canada ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Mexico ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. UK ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Germany ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. France ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Italy ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Spain ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Denmark ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Competitive Scenario
      • 7.4.8.3. Regulatory Framework
      • 7.4.8.4. Sweden ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Competitive Scenario
      • 7.4.9.3. Regulatory Framework
      • 7.4.9.4. Norway ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Japan ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. China ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. India ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Australia ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Thailand ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. South Korea
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. South Korea ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Brazil ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Argentina ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. South Africa ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Saudi Arabia ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. UAE ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Kuwait ADME Toxicology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Categorization
  • 8.2. Company Market Position Analysis, 2024
  • 8.3. Participant's Overview
    • 8.3.1. Thermo Fisher Scientific Inc.
      • 8.3.1.1. Overview
      • 8.3.1.2. Product Benchmarking
      • 8.3.1.3. Strategic Initiatives
    • 8.3.2. Danaher
      • 8.3.2.1. Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Charles River Laboratories
      • 8.3.3.1. Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Promega Corporation
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Agilent Technologies, Inc.
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Curia Global, Inc.
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Dassault Systemes
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Catalent, Inc
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Labcorp
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Eurofins Scientific
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. Miltenyi Biotec
      • 8.3.11.1. Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Product Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. IQVIA Inc.
      • 8.3.12.1. Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Product Benchmarking
      • 8.3.12.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦